



Vita Life Sciences Limited

ACN 003 190 421

ABN 35 003 190 421

Corporate Office

Suite 802, Level 8,

1-5 Chalmers Crescent

Mascot NSW 2020

Australia

T: 61 2 9545 2633

F: 61 2 9545 1311

vitalifesciences.com

12 June 2026

Market Announcements
Australian Securities Exchange Ltd
Level 27, 39 Martin Place,
Sydney, NSW 2000

GUIDANCE

Vita Life Sciences (ASX: VLS) announces the following guidance for the half year ending 30 June 2026:

Sales: \$46.3m-\$47.3m (H1 2025: \$45.5m)

Pre-tax Profit: \$6.8m-7.3m (H1 2025: \$6.8m)

The Company's expects solid revenue growth from its established markets in Australia and Malaysia/Singapore, partially offset by lower exports to China due to a changing regulatory environment and channel dynamics.

Pre-tax profit is expected to be in line or slightly higher than the prior corresponding period reflecting continued cost discipline and the underlying quality of earnings despite tougher economic conditions.

Importantly, the Group's underlying financial position remains sound with substantial cash reserves, no borrowings and continued cash generation supporting ongoing investment in strategic priorities.

The Group remains focussed on its long-term strategy and remains committed to delivering long term sustainable growth and value for shareholders.

Andrew O'Keefe
Managing Director

Email: enquiries@vitalifesciences.com.au

For personal use only